TLPH TALPHERA, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1427925 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-96.3%
TTM net income YoY-33.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,474,700.0%
Net margin-1,507,600.0%
FCF margin—
EBITDA margin—
Returns
ROE-143.4%
ROA-69.6%
ROIC (approx.)-172.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets46.3%
Debt / equity0.00x
Current ratio4.29x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-13.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $28,000 | $0 |
| R&D expense | $6.03M | $6.72M |
| SG&A expense | $7.48M | $8.53M |
| Operating income | -$13.48M | -$15.25M |
| Interest expense | — | $0 |
| Income tax | $0 | $0 |
| Net income | -$14.29M | -$13.00M |
| EBITDA | — | -$15.25M |
| EPS (basic) | -0.34 | -0.50 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $5.89M | $8.86M |
| Short-term investments | $14.49M | $0 |
| Current assets | $20.90M | $9.42M |
| Intangibles | $8.82M | $8.82M |
| Total assets | $29.72M | $18.24M |
| Current liabilities | $3.81M | $2.65M |
| Total liabilities | $12.68M | $10.23M |
| Shareholders' equity | $17.04M | $8.00M |
| Shares outstanding | 49.33M | 17.03M |
| Cash flow statement | ||
| Operating cash flow | -$11.36M | -$12.68M |
| Capital expenditure | — | $0 |
| Free cash flow | — | -$12.68M |
| Investing cash flow | -$14.35M | $3.78M |
| Financing cash flow | $22.74M | $12.04M |
| Depreciation & amortization | — | $0 |
| Stock-based compensation | $699,000 | $989,000 |
Free plan shows the latest 2 periods; Pro shows all 20 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.